Clinical trial
A Single-masked, Randomized, Multi-center, Parallel-group, 4-week Study Evaluating the Efficacy and Safety of Once Daily Netarsudil Ophthalmic Solution 0.02% Compared to Twice Daily Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% in Japanese Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
NCT04620135 is registered in ClinicalTrials.gov with Aerie Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-masked, Randomized, Multi-center, Parallel-group, 4-week Study Evaluating the Efficacy and Safety of Once Daily Netarsudil Ophthalmic Solution 0.02% Compared to Twice Daily Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% in Japanese Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
- Lead sponsor
- Aerie Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2020
- Completion date
- July 30, 2021
- Enrollment
- 245 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ocular hypertension, primary open angle glaucoma